Linfoma canino

Revisão de literatura com ênfase no linfoma difuso de grandes células B

  • Maria Claudia Lopes Silva
  • Julio Lopes Sequeira
Palavras-chave: linfoma, cão, DLBCL, imunofenotipagem

Resumo

Os linfomas não Hodgkin (LNHs) são as neoplasias hematopoiéticas mais comuns nos cães,
no entanto, sua etiologia não está bem estabelecida e há diversos fatores que devem contribuir
para seu desenvolvimento, como alterações no sistema imune, fatores ambientais e alterações
genéticas. A neoplasia pode ocorrer em qualquer idade, mas afeta, predominantemente,
animais de meia idade a idosos. Anatomicamente, os linfomas caninos podem ser
classificados em: multicêntrico, digestivo, tímico, cutâneo e solitário, com cinco estágios
clínicos e dois subestágios. Nos últimos anos, foram utilizadas diversas classificações
humanas, além de classificação proposta para os animais domésticos. A imunofenotipagem
dos linfomas está incorporada aos sistemas mais atuais de classificação, assim como a
determinação da expressão de marcadores biológicos de proliferação e apoptose. O Linfoma
Difuso de Grandes Células B (DLBCL) é o subtipo mais frequente, tanto no cão quanto em
humanos. Os DLBCLs são neoplasias formadas por células linfoides B caracterizadas por um
padrão de crescimento difuso e podem apresentar pelo menos cinco variantes que estão
relacionadas com padrões distintos de comportamento biológico, inclusive nos cães. No
entanto, rotineiramente, estes tumores são apenas classificados como DLBCLs sem considerar
suas particularidades morfológicas, seu perfil imunoistoquímico e seu índice proliferativo. Por
isso, a World Health Organization (WHO) propõe que, nos trabalhos de pesquisa, estas
variantes sejam investigadas detalhadamente com o intuito de identificar as diferenças que
possibilitem discriminar novas entidades.

Referências

Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, et al. A

morphological study of 608 cases of canine malignant lymphoma in France with a focus on

comparative similarities between canine and human lymphoma morphology. Vet Pathol.

;47(3):414-33.

Comazzi S, Guscetti F, Marconato L. First meeting of the European canine lymphoma

group. Workshop: state of the art and comparative aspects in canine lymphoma. CHLugano, 22 June 2013. Hematol Oncol. 2013;32(2):68-71.

Ito D, Frantza AM, Modiano JF. Canine lymphoma as a comparative model for humannonHodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol.

;159(3-4):192-201.

Valli VE, Jacobs RM, Parodi AL, Vernau W, Moore PF. Histological classification of

hematopoietic tumors of domestic animals. 2nd ed. Washington: Armed Forced Institute of

Pathology; 2002.

Valli VE, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzly F, et al. Classification

of canine malignant lymphomas according to the World Health Organization Criteria. Vet

Pathol. 2011;48(1):198-211.

Frantz AM, Sarver AL, Ito D, Phang TL, Karimpour-Fard A, Scott MC, et al. Molecular

profiling reveals prognostically significant subtypes of canine lymphoma. Vet Pathol.

;50(4):693-703.

Mudaliar MAV, Haggart RD, Miele G, Sellar G, Tan KA, Goodlad JR, et al. Comparative

gene expression profiling identifies common molecular signatures of NF-kB activation in

canine and human diffuse large B cell lymphoma (DLBCL). PLOS One. 2013;8(9):1-17.

Richards KL, Motsinger-Reif AA, Chen H, Fedoriw Y, Fan C, Nielsen DM, et al. Gene

profiling of canine B-cell lymphoma reveals germinal center and post-germinal center

subtypes with different survival times, modeling human DLBCL. Cancer Res.

;73(16):5029-39.

Suzano SMC. Avaliação da proliferação celular, índice apoptótico e da expressão do P53

nos linfomas caninos [tese]. Botucatu: Faculdade de Medicina Veterinária e Zootecnia,

Universidade Estadual Paulista ; 2007.

Valli VE. Veterinary comparative hematopathology. Iowa: Blackwell; 2007.

Donoghue S, Baden HS, Lauder I, Sobolewski S, Pringle JH. Immunohistochemical

localization of caspase-3 correlates with clinical outcome in B-Cell Diffuse Large-Cell

Lymphoma. Cancer Res. 1999;59(20):5386-91.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO

Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC

Press; 2008.

Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood.

;84(8):2412-21.

Sueiro FAR, Alessi AC, Vassallo J. Canine lymphomas: a morphological and

immunohistochemical study of 55 cases, with observations on p53 immunoexpression. J

Comp Pathol. 2004;131(2-3):207-13.

Dhaliwal RS, Kitchell BE, Ehrhart EJ, Valli VE, Dervisis NG. Clinicopathologic

significance of histologic grade, Pgp, and P53 expression in canine lymphoma. J Am

Anim Hosp Assoc. 2013;49(3):175-85.

Tomiyasu H, Goto-Koshino Y, Takahashi M, Fujino Y, Ohno K, Tsujimoto H.

Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with

lymphoma. J Vet Med Sci. 2010;72(9):1165-72.

Dobson JM, Blackwood LB, Mcinnes EF, Bostock DE, Nicholls P, Hoather TM, et al.

Prognostic variables in canine multicentric lymphossarcoma. J Small Anim Pract.

;42(8):377-84.

Rutley M, MacDonald V. Managing the canine lymphosarcoma patient in general

practice. Can Vet J. 2007;48(9):977-9.

Vail DM, MacEwen EG, Young KM. Canine lymphoma and lymphoid leukemias. In:

Withrow SJ, MacEwen EG. Small animal clinical oncology. 3rd ed. Philadelphia:

Saunders Company; 2001. p.558-90.

Boerkamp KM, Teske E, Boon LR, Grinwis GCM, van den Bossche L, Rutteman GR.

Estimated incidence rate and distribution of tumours in 4,653 cases of archival

submissions derived from the Dutch golden retriever population. BMC Vet Res.

;10(34):1-10.

Teske E. Canine malignant lymphoma: a review and comparison with human non

hodgkin's lymphoma. Vet Q. 1994;16(4):209-19.

Zanini DA, Kimura KC, Nishiya AT, Ubukata R, Leandro RM, Brito CP, et al.

Environmental risk factors related to the development of canine non-Hodgkin’s

Lymphoma Cienc Rural. 2013;43(7):1302-8.

Rütgen BC, Willenbrock S, Reimann-Berg N, Walter I, Fuchs-Baumgartinger A, Wagner

S, et al. Authentication of primordial characteristics of the CLBL- 1 cell line prove the

integrity of a canine B-Cell lymphoma in a murine in vivo model. PLoS One.

;7(6):e40078. doi:10.1371/journal.pone.0040078.

Ferraresso S, Bresolin S, Arico A, Comazzi S, Gelain ME, Riondato F, et al. Epigenetic

silencing of TFPI-2 in canine diffuse large BCell lymphoma. PLOS One. 2014;9(4):1-10.

Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer.

Trends Mol Med. 2011;17(7):380-8.

Vail DM, Young KM. Hematopoietic tumors. In: Withrow SJ, Vail DM. Small animal

clinical oncology. 4th ed. Missouri: Saunders; 2007. p.699-784.

Moreno K, Bracarense APFRL. Estudo retrospectivo de linfoma canino no período de

-2004 na região norte do Paraná. Braz J Vet Res Anim Sci. 2007;44:46-52.

Cápua MLB, Coleta FED, Canesin APMN, Godoy AV, Calazans SG, Miotto MR, et al.

Linfoma canino: clínica, hematologia e tratamento com o protocolo de MadisonWisconsin. Cienc Rural. 2011;41(7):1245-51.

Neuwald EB, Teixeira LV, Conrado FO, Silva MOD, Hlavac NRC, González FHD.

Epidemiological, clinical and immunohistochemical aspects of canine lymphoma in the

region of Porto Alegre, Brazil. Pesqui Vet Bras. 2014;34(4):349-54.

Sequeira JL, Franco M, Bandarra EP, Figueiredo LMA, Rocha NS. Características

anatomoclínicas dos linfomas caninos na região de Botucatu, São Paulo. Arq Bras Med

Vet Zootec. 1999;51(3):245-9.

Fighera RA, Souza TM, Rodrigues A, Barros CSL. Aspectos clinicopatológicos de 43

casos de linfoma em cães. MEDVEP: Rev Cient Med Vet Pequenos Anim Anim Estim.

;4(12):139-46.

Vezzali E, Parodi AL, Marcato PS, Bettini, G. Histopathologic classification of 171 cases

of canine and feline non Hodgkin lymphoma according to the WHO. Vet Comp Oncol.

;8(1):38-49.

Fernandes TR. Classificação morfológica e imunoistoquímica em microarranjo de tecido

(TMA) de linfomas não-hodgkin em cães conforme os critérios da Histological

Classification of Hematopoietic Tumours of Domestic Animals (WHO) [dissertação].

Botucatu: Faculdade de Medicina Veterinária e Zootecnia, Universidade Estadual

Paulista; 2014.

Pastor M, Chalvet-Monfray K, Marchal T, Keck G, Magnol JP, Fournel-Fleury C, et al.

Genetic and environmental risk indicators in canine non-hodgkin’s lymphomas: breed

associations and geographic distribution of 608 cases diagnosed throughout France over 1

year. J Vet Intern Med. 2009;23(2):301-10.

Valli VE, Kass PH, San Myint M, Scott F. Canine lymphomas: association of

classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.

Vet Pathol. 2013;50(5):738-48.

Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R, et al. Distinct B-cell

and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable

risk. Cancer Res. 2005;65(13):5654-61.

Dobson JM. Breed-Predispositions to cancer in pedigree dogs. ISRN Vet

Sci. 2013;2013:1-23. doi:10.1155/2013/941275.

Bienzle D, Vernau W. The diagnostic assessment of canine lymphoma: implications for

treatment. Clin Lab Med. 2011;31(1):21-39.

Flowers R, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell

lymphoma. CA Cancer J Clin. 2010;60(6):393-408.

Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H,

Vardiman JW. World health organization classification of tumors. Pathology and genetics

of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p.171-4.

Lennert K, Feller AC. Histopathology of non-hodgkin´s lymphomas. 2nd ed. Berlim:

Springer-Verlag; 1992.

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al.

The World Health Organization classification of neoplastic diseases of the hematopoietic

and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House,

Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-49.

Suzano SMC, Sequeira JL, Rocha NS, Pessoa AWP. Classificação citológica dos

linfomas caninos. Braz J Vet Res Anim Sci. 2010;47(1):47-54.

Thalheim L, Williams LE, Borst LB, Fogle JE, Suter SE. Lymphoma immunophenotype

of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain

reaction for antigen receptor rearrangements. J Vet Intern Med. 2013;27(6):1509-16.

O'Mahony OH, Riley A. CD20-negative follicular lymphoma. Diagn Histophatol.

;18(10):457-60.

Marconato L, Gelain ME, Comazzi S. The dog as a possible animal model for human

non- Hodgkin lymphoma: a review. Hematol Oncol. 2013;31(1):1-9.

Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of

surface antigen expression in common B-cell malignancies using flow cytometry.

Immunol Invest. 2006;35(1):93-114.

Polson AG, Yu S, Elkins K, Zheng B, Clark S, Ingle GS, et al. Antibody-drug conjugates

targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110(2):616-

Kano R, Inoiue C, Okano H, Yamazaki J, Takahashi T, Watari T, et al. Canine CD20

gene. Vet Immunol Immunopathol. 2005;108(3-4):265-8.

Torlakovic E, Slipicevic A, Robinson C, Decoteau JF, Alfsen GC, Vyberg M, et al. Pax-5

expression in nonhematopoietic tissues. Am J Clin Pathol. 2006;126(5):798-804.

Taylor RP, Lindorfer MA. Analyses of CD20 monoclonal antibody-mediated tumor cell

killing mechanisms: rational design of dosing strategies. Mol Pharmacol.

;86(5):485-91.

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the

efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20

antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity.

Blood. 2010;115(22):4393-402.

Franke A, Niederfellner GJ, Klein C, Burtscher H. Antibodies against CD20 or B-cell

receptor induce similar transcription patterns in human lymphoma cell lines. PLoS

One. 2011;18(2):e16596. doi: 10.1371/journal.pone.0016596.

Kiupel M, Teske E, Bostock D. Prognostic factors for treated canine malignant

lymphoma. Vet Pathol. 1999;36(4):292-300.

Suzano SMC, Sequeira JL, Pessoa AWP, Porto CD, Oliveira DE. Proliferação celular nos

linfomas caninos. Braz J Vet Res Anim Sci. 2008;45(4):313-9.

Zacchetti A, Van Garderen E, Teske E, Nederbragt H, Dierendonck JH, Rutteman GR.

Validation of the use of proliferation markers in canine neoplastic and non-neoplastic

tissues: comparison of Ki-67 and proliferating cell nuclear antigen (PCNA) expression

versus in vivo bromodeoxyuridine labeling by immunohistochemistry. APMIS.

;111(3):430-8.

Phillips BB, Kass PH, Naydan DK, Winthrop MD, Griffey SM, Madewell BR. Apoptotic

and proliferation indexes in canine lymphoma. J Vet Diagn Invest. 2000;12(2):111-7.

Dukers DF, Oudejans JJ, Vos W, Berge RL, Meijer CJLM. Apoptosis in B-cell

lymphomas and reactive lymphoid tissues always involves activation of caspase-3 as

determined by a new in situ detection method. J Pathol. 2002;196(3):307-15.

Sokolowska J, Cywinska A, Malicka E. p53 expression in canine lymphoma. J Vet Med.

;52(4):172-5.

Publicado
20-12-2016
Como Citar
Lopes Silva, M. C., & Lopes Sequeira, J. (2016). Linfoma canino: Revisão de literatura com ênfase no linfoma difuso de grandes células B. Veterinária E Zootecnia, 23(4), 571-576. Recuperado de https://rvz.emnuvens.com.br/rvz/article/view/407
Seção
Artigos de Revisão